<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02984683</url>
  </required_header>
  <id_info>
    <org_study_id>ACT14884</org_study_id>
    <secondary_id>2016‐001962‐27</secondary_id>
    <secondary_id>U1111-1182-7044</secondary_id>
    <nct_id>NCT02984683</nct_id>
  </id_info>
  <brief_title>Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer</brief_title>
  <official_title>Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To select in the first part the SAR566658 dose based on Objective Response Rate (ORR) and
      safety of 2 dose levels and to demonstrate in the second part the efficacy of the selected
      dose based on ORR.

      Secondary Objectives:

        -  To assess:

        -  Disease Control Rate (DCR), Duration Of Response (DOR), Progression-Free Survival (PFS),
           and Time To Progression (TTP)

        -  The impact of ocular primary prophylaxis on the incidence of keratopathies;

        -  The potential immunogenicity of SAR566658

        -  To evaluate the global safety profile
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study for 1 patient will include a screening period of up to 21 days
      prior to first study drug administration, 3-week treatment cycle(s) (until 30 days after last
      SAR566658 administration), and a follow-up period. Each patient will be treated until
      radiological disease progression, unacceptable toxicity, or patient's refusal of further
      study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Anticipated">December 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response - time</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival - time</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of keratopathies</measure>
    <time_frame>Up to 30 days after the 3-week treatment cycle(s) (until 30 days after last treatment administration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of positive patients for antidrug antibodies as a measure of SAR566658 immunogenicity</measure>
    <time_frame>Up to 60 days after the 3-week treatment cycle(s) (until 60 days after last treatment administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SAR566658 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR566658 will be given as Dose 1 (cohort 1) and Dose 2 (cohort 2) at Day 1 and Day 8 every 3 weeks intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR566658 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR566658 (Part 2) - SAR566658 will be given as Dose 1 or Dose 2 (depending on dose level selected from part 1) at Day 1 and Day 8 every 3 weeks intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR566658 (ACT14884)</intervention_name>
    <description>Pharmaceutical form:Solution Route of administration: Intravenous</description>
    <arm_group_label>SAR566658 (Part 2)</arm_group_label>
    <arm_group_label>SAR566658 (Part 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Measurable Metastatic triple negative breast cancer (TNBC).

          -  Patients with CA6-positive disease.

          -  Patients received at least 1 prior chemotherapy regimen but no more than 3 for
             advanced/metastatic disease.

          -  Prior anticancer therapy must have contained anthracycline (eg, doxorubicin), if not
             contraindicated, and a taxane (eg, docetaxel, paclitaxel) in an adjuvant/neo-adjuvant
             or metastatic setting.

        Exclusion criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≥2.

          -  Patient less than 18 years old.

          -  Pregnant or breast-feeding women.

          -  Patients with reproductive potential who do not agree to use accepted and effective
             method of contraception during the study treatment period and for 6 months following
             discontinuation of study drug.

          -  Wash out period of less than 3 weeks or 5 half-lives from previous antitumor
             chemotherapy, immunotherapy, or any investigational treatment.

          -  History of brain metastasis (other than totally resected or previously irradiated and
             nonprogressive/relapsed), spinal cord compression or carcinomatous meningitis, or new
             evidence of brain leptomeningeal disease.

          -  Prior treatment with eribulin as last prior therapy or prior maytansinoid treatments
             (DM1 or DM4 antibody-drug conjugates [ADCs]).

          -  Known intolerance to infused protein products including other monoclonal antibodies
             and ADCs.

          -  Poor bone marrow reserve and/or poor organ function.

          -  Symptomatic peripheral neuropathy Grade ≥2.

          -  Previous history of chronic corneal diseases (even if asymptomatic) or unresolved
             acute nonrecurrent corneal conditions.

          -  Patients wearing contact lenses who are not willing to stop wearing them for the
             duration of the study.

          -  Medical conditions requiring concomitant administration of strong CYP3A4 inhibitors,
             unless it can be discontinued at least 2 weeks before 1st administration of SAR566658.

          -  Contraindications to the use of ophthalmic vasoconstrictor and/or corticosteroid.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400003</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400002</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560002</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0560001</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030002</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030003</name>
      <address>
        <city>Zlin</city>
        <zip>76275</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800002</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800004</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280001</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280002</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240002</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240005</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240007</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240006</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240003</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240004</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2016</study_first_submitted>
  <study_first_submitted_qc>December 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

